Cargando…
Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective
Half of the patients with ulcerative colitis require at least one course of systemic corticosteroids in their lifetime. Approximately 75% of these patients will also require immunosuppressive drugs (i.e., thiopurines or biological agents) in the mid-term to avoid colectomy. Immunosuppressive drugs r...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968132/ https://www.ncbi.nlm.nih.gov/pubmed/33776362 http://dx.doi.org/10.3748/wjg.v27.i10.908 |
_version_ | 1783666000737075200 |
---|---|
author | Domènech, Eugeni Grífols, Joan-Ramon Akbar, Ayesha Dignass, Axel U |
author_facet | Domènech, Eugeni Grífols, Joan-Ramon Akbar, Ayesha Dignass, Axel U |
author_sort | Domènech, Eugeni |
collection | PubMed |
description | Half of the patients with ulcerative colitis require at least one course of systemic corticosteroids in their lifetime. Approximately 75% of these patients will also require immunosuppressive drugs (i.e., thiopurines or biological agents) in the mid-term to avoid colectomy. Immunosuppressive drugs raise some concerns due to an increased risk of serious and opportunistic infections and cancer, particularly in elderly and co-morbid patients, underlining the unmet need for safer alternative therapies. Granulocyte/monocytapheresis (GMA), a CE-marked, non-pharmacological procedure for the treatment of ulcerative colitis (among other immune-mediated diseases), remains the only therapy targeting neutrophils, the hallmark of pathology in ulcerative colitis. GMA has proven its efficacy in different clinical scenarios and shows an excellent and unique safety profile. In spite of being a first line therapy in Japan, GMA use is still limited to a small number of centres and countries in Europe. In this article, we aim to give an overview from a European perspective of the mechanism of action, recent clinical data on efficacy and practical aspects for the use of GMA in ulcerative colitis. |
format | Online Article Text |
id | pubmed-7968132 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-79681322021-03-25 Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective Domènech, Eugeni Grífols, Joan-Ramon Akbar, Ayesha Dignass, Axel U World J Gastroenterol Opinion Review Half of the patients with ulcerative colitis require at least one course of systemic corticosteroids in their lifetime. Approximately 75% of these patients will also require immunosuppressive drugs (i.e., thiopurines or biological agents) in the mid-term to avoid colectomy. Immunosuppressive drugs raise some concerns due to an increased risk of serious and opportunistic infections and cancer, particularly in elderly and co-morbid patients, underlining the unmet need for safer alternative therapies. Granulocyte/monocytapheresis (GMA), a CE-marked, non-pharmacological procedure for the treatment of ulcerative colitis (among other immune-mediated diseases), remains the only therapy targeting neutrophils, the hallmark of pathology in ulcerative colitis. GMA has proven its efficacy in different clinical scenarios and shows an excellent and unique safety profile. In spite of being a first line therapy in Japan, GMA use is still limited to a small number of centres and countries in Europe. In this article, we aim to give an overview from a European perspective of the mechanism of action, recent clinical data on efficacy and practical aspects for the use of GMA in ulcerative colitis. Baishideng Publishing Group Inc 2021-03-14 2021-03-14 /pmc/articles/PMC7968132/ /pubmed/33776362 http://dx.doi.org/10.3748/wjg.v27.i10.908 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Opinion Review Domènech, Eugeni Grífols, Joan-Ramon Akbar, Ayesha Dignass, Axel U Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective |
title | Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective |
title_full | Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective |
title_fullStr | Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective |
title_full_unstemmed | Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective |
title_short | Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective |
title_sort | use of granulocyte/monocytapheresis in ulcerative colitis: a practical review from a european perspective |
topic | Opinion Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7968132/ https://www.ncbi.nlm.nih.gov/pubmed/33776362 http://dx.doi.org/10.3748/wjg.v27.i10.908 |
work_keys_str_mv | AT domenecheugeni useofgranulocytemonocytapheresisinulcerativecolitisapracticalreviewfromaeuropeanperspective AT grifolsjoanramon useofgranulocytemonocytapheresisinulcerativecolitisapracticalreviewfromaeuropeanperspective AT akbarayesha useofgranulocytemonocytapheresisinulcerativecolitisapracticalreviewfromaeuropeanperspective AT dignassaxelu useofgranulocytemonocytapheresisinulcerativecolitisapracticalreviewfromaeuropeanperspective |